Immunovant Inc (IMVT NASDAQ) stock market data APIs
$15.0109
0.27(1.8%)
as of September 17, 2025
Try our APIs with
free plan!
Immunovant Inc Financial Data Overview
Price chart is built with
Anychart
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Prev. Close
15.0109
Open
15.2786
High
15.7146
Low
15.118
52 wk Range
12.72-32.1
Market Cap
2 634 M
Shares Outstanding
174 M
EPS
-0.71
Beta
0.444
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunovant Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunovant Inc data using free add-ons & libraries
Get Immunovant Inc Fundamental Data
Immunovant Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -470 691 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: -0.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunovant Inc News
New
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant�...
Notable Thursday Option Activity: IMVT, RBLX, MEG
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Immunovant Inc (Symbol: IMVT), where a total volume of 6,555 contracts has been tr...
Roivant Sciences (ROIV) Is Up 9.4% After Positive Immunovant Data and Japan Orphan Drug Nod - What's Changed
Roivant Sciences recently announced promising proof-of-concept study results from subsidiary Immunovant on batoclimab for uncontrolled Graves’ Disease and received orphan drug designation in Japan f...
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Immunovant, Inc. (IMVT). Shares have added about 7.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue lea...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
